TargetMol

Sograzepide

Product Code:
 
TAR-T16906
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T16906-50mg50mg£1,002.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16906-100mg100mg£1,468.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively).
CAS:
155488-25-8
Formula:
C28H30N6O3
Molecular Weight:
498.587
Purity:
0.98
SMILES:
CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1

References

1. Boyce M, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015 May;79(5):744-55. 2. Takinami Y, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.Aliment Pharmacol Ther. 1997 Feb;11(1):113-20.